Advanced search
Publication Cover
Leukemia & Lymphoma Volume 64, 2023 - Issue 3
Submit an article Journal homepage
4,169
Views
1
CrossRef citations to date
0
Altmetric
Original Articles

Use of a real-world synthetic control arm for direct comparison of lisocabtagene maraleucel and conventional therapy in relapsed/refractory large B-cell lymphoma

Hoa Van Lea Biometrics and Data Sciences, Bristol Myers Squibb, Princeton, NJ, USAView further author information
,
Kim Van Naarden Braunb Translational Epidemiology, Bristol Myers Squibb, Princeton, NJ, USACorrespondence[email protected]
View further author information
,
Grzegorz S. Nowakowskic Hematology, Mayo Clinic, Rochester, MN, USAView further author information
,
David Sermerd Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USAORCID Iconhttps://orcid.org/0000-0003-0528-7728View further author information
ORCID Icon,
John Radforde Department of Medical Oncology, The Christie NHS Foundation Trust and University of Manchester, Manchester Academic Health Science Centre, Manchester, UKView further author information
,
William Townsendf Hematology, University College London Hospitals NHS Foundation Trust, London, UKView further author information
,
Herve Ghesquieresg Department of Hematology, Hôpital Lyon Sud, Lyon, FranceORCID Iconhttps://orcid.org/0000-0002-3131-3718View further author information
ORCID Icon,
Tobias Menneh Hematology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Northumberland, UKView further author information
,
Edit Porpaczyi Comprehensive Cancer Center, Medical University of Vienna, Vienna, AustriaView further author information
,
Christopher P. Foxj Department of Clinical Hematology, Nottingham University Hospitals NHS Trust, Nottingham, UKView further author information
,
Claudia Schusterbauerk Clinical Research and Development, Celgene, a Bristol-Myers Squibb Company, Boudry, SwitzerlandView further author information
,
Fei Fei Liul Worldwide Health Economics and Outcomes Research CAR T, Bristol Myers Squibb, Princeton, NJ, USAView further author information
,
Lihua Yuem Statistics, Bristol Myers Squibb, Princeton, NJ, USAView further author information
,
Marc De Benedettia Biometrics and Data Sciences, Bristol Myers Squibb, Princeton, NJ, USAView further author information
&
Jens Hasskarln Cell Therapy Development, Celgene, a Bristol-Myers Squibb Company, Boudry, SwitzerlandView further author information
 show all
Pages 573-585 | Received 08 Jul 2022, Accepted 08 Dec 2022, Published online: 08 Feb 2023

References

  • Martelli M, Ferreri AJ, Agostinelli C, et al. Diffuse large B-cell lymphoma. Crit Rev Oncol Hematol. 2013;87(2):146–171.
  • Tilly H, Gomes da Silva M, Vitolo U, et al. Diffuse large B-cell lymphoma (DLBCL): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(suppl 5):v116–v125.
  • Van Den Neste E, Schmitz N, Mounier N, et al. Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study. Bone Marrow Transplant. 2017;52(2):216–221.
  • van Imhoff GW, McMillan A, Matasar MJ, et al. Ofatumumab versus rituximab salvage chemoimmunotherapy in relapsed or refractory diffuse large B-cell lymphoma: the ORCHARRD study. J Clin Oncol. 2017;35(5):544–551.
  • Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800–1808.
  • Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396(10254):839–852.
  • Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531–2544.
  • Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380(1):45–56.
  • Salles G, Spin P, Liu FF, et al. Indirect treatment comparison of liso-cel vs. salvage chemotherapy in diffuse large B-cell lymphoma: TRANSCEND vs. SCHOLAR-1. Adv Ther. 2021;38(6):3266–3280.
  • Rosenbaum P, Rubin DB. The Central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70(1):41–55.
  • Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28(25):3083–3107.
  • González-Barca E, Boumendil A, Blaise D, et al. Outcome in patients with diffuse large B-cell lymphoma who relapse after autologous stem cell transplantation and receive active therapy. A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 2020;55(2):393–399.
  • Van Den Neste E, Schmitz N, Mounier N, et al. Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the international CORAL study. Bone Marrow Transplant. 2016;51(1):51–57.
  • Neelapu SS, Locke FL, Bartlett NL, et al. A comparison of two-year outcomes in ZUMA-1 (axicabtagene ciloleucel) and SCHOLAR-1 in patients with refractory large B cell lymphoma. Blood. 2019;134(suppl 1):4095.
  • Sermer D, Batlevi C, Palomba ML, et al. Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies. Blood Adv. 2020;4(19):4669–4678.
  • Graham JW, Olchowski AE, Gilreath TD. How many imputations are really needed? Some practical clarifications of multiple imputation theory. Prev Sci. 2007;8(3):206–213.
  • van Buuren S. How many imputations?. In: van Buuren S, editor. Flexible imputation of missing data. 2nd ed. New York: Chapman & Hall/CRC; 2018. p. 58–60.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.